Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCT-2138 self-amplifying mRNA influenza vaccine in healthy adults
NCT06125691Phase 1Completed
- Sponsor
- Arcturus Therapeutics
- Start
- Jan 2024
- Primary completion
- Aug 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of ARCT-2138 in influenza (9 arms), sponsored by Arcturus Therapeutics. Primary endpoints: Local Adverse Events at 14 days, Systemic Adverse Events at 14 days and 5 more. Started Jan 2024; status: completed.
02
Drugs
ARCT-2138
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06125691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06125691.